Medicine & Life Sciences
Hepacivirus
100%
sofosbuvir drug combination ledipasvir
81%
Hepatitis C
71%
HIV
47%
Sustained Virologic Response
33%
Chronic Hepatitis C
32%
Ribavirin
30%
Randomized Controlled Trials
28%
velpatasvir
25%
Pharmaceutical Preparations
21%
Continuity of Patient Care
21%
Sofosbuvir
20%
Alcohols
20%
2-(pyrrolidin-2-yl)-5-(2-(4-(5-(pyrrolidin-2-yl)-1H-imidazol-2-yl)phenyl)benzofuran-5-yl)-1H-imidazole
19%
Antiviral Agents
19%
phosphatidylethanol
18%
Enterobacter cloacae
18%
Sexual and Gender Minorities
17%
Therapeutics
17%
Infections
16%
Haemolytic Anaemia
16%
Sickle Cell Anemia
15%
Chronic Hepatitis
14%
Motivation
14%
Confidence Intervals
14%
Endocarditis
14%
Virus Diseases
13%
Interferons
12%
Mentors
12%
Income
11%
Primary Health Care
10%
Public Health
9%
Safety
9%
Genome
9%
Medication Adherence
9%
Population
9%
Enterobacter
8%
Substance-Related Disorders
8%
Genotype
7%
Intravenous Substance Abuse
6%
Incidence
6%
RNA
5%